Regenerative Research Foundation
- Assets
- $6.0m
- Revenue
- $7.5m
- Investments
- $0.0
- Employees
- 43
- Location
- Rensselaer, NY
- Founding
- 11/2007
- Data as of
- 12/2022
- EIN
- 20-3654626
Organization Overview
Regenerative Research Foundation, operating under the name Neural Stem Cell Institute, is located in Rensselaer, NY. The organization was established in 2007. According to its NTEE Classification (H96) the organization is classified as: Neurology & Neuroscience Research, under the broad grouping of Medical Research and related organizations. As of 12/2022, Neural Stem Cell Institute employed 43 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Neural Stem Cell Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Neural Stem Cell Institute generated $7.5m in total revenue. This represents relatively stable growth, over the past 8 years the organization has increased revenue by an average of 2.2% each year. All expenses for the organization totaled $5.8m during the year ending 12/2022. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA.
Describe the Organization's Program Activity:
Part 3 - Line 4a
FISCAL YEAR 2022 SAW THE REGENERATIVE RESEARCH FOUNDATION'S OPERATIONS RETURN TO A MORE NORMAL LEVEL OF ACTIVITY. THE LABORATORIES WERE FULLY STAFFED, AND THE FOUNDATION RENEWED ITS COMMITMENT TO PURSUING ITS MISSION TO DEVELOP POTENTIAL THERAPIES FOR TREATMENT FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM. FOUNDATION RESEARCHERS PUBLISHED A TOTAL OF SEVEN ARTICLES REPORTING THE RESULTS OF THEIR INVESTIGATIONS IN SEVERAL PROMINENT SCIENTIFIC JOURNALS. THE TOPICS INCLUDED NEURODEGENERATIVE, EYE AND ALZHEIMER'S DISEASE. THESE ARTICLES ARE MADE AVAILABLE FREELY TO THE SCIENTIFIC COMMUNITY AND THE GENERAL PUBLIC THROUGH THE NATIONAL INSTITUTES OF HEALTH PUB-MED CENTRAL PUBLICATION RETRIEVAL SYSTEM. INVESTIGATORS AT THE FOUNDATION WERE ABLE TO SECURE 10 NEW RESEARCH GRANTS TO CONTINUE AND EXPAND THE STEM CELL RESEARCH PROGRAMS.
THE FOUNDATION INITIATED ITS PLANNED CLINICAL TRIAL DURING FISCAL YEAR 2022 AFTER SURMOUNTING NUMEROUS OBSTACLES INCLUDING THE PANDEMIC AND RETINAL STEM CELL PRODUCT MANUFACTURING DELAYS. THREE STUDY SUBJECTS RECEIVED THE RETINAL PIGMENT EPITHELIUM STEM CELL REPLACEMENT THERAPY DEVELOPED BY THE FOUNDATION. THE RESULTS OF THIS THERAPEUTIC INTERVENTION FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION ARE PROMISING. THE FOUNDATION HOPES TO EXPAND THESE CLINICAL STUDIES WITH ITS BIOTECHNOLOGY PARTNERSHIP AND MAKE THE THERAPY READILY AVAILABLE TO THOSE SUFFERING FROM AMD.
THE ALZHEIMER'S AND RELATED DEMENTIA RESEARCH PROGRAM CONTINUED ITS INVESTIGATIONS INTO THE CAUSES AND TREATMENT OF THESE DISEASES. THE FOUNDATION ALSO EXPANDED ITS DEMENTIA PROGRAM BY ESTABLISHING SEVERAL COLLABORATIVE ARRANGEMENTS INCLUDING A PROJECT INVOLVING FIVE COLLABORATIVE LABORATORIES AT DIFFERENT ACADEMIC INSTITUTIONS. SUPPORT FOR THESE ENDEAVORS WAS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH AND VARIOUS PUBLIC CHARITIES. IN ADDITION, THE FOUNDATION ENTERED INTO AN AGREEMENT WITH A BIOTECHNOLOGY COMPANY TO RESEARCH A POTENTIAL NEURODEGENERATIVE DISEASE TREATMENT.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
William Kahn CPA Chair | OfficerTrustee | 5 | $0 |
Jeffrey H Stern MD PHD Director For Translational | OfficerTrustee | 30 | $47,400 |
John Walsh Director | Trustee | 2 | $0 |
Vito Grasso Mpa Cae Director | Trustee | 1 | $0 |
David O Carpenter MD Director | Trustee | 1 | $0 |
Dawn Abbuhl Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $5,578,681 |
| All other contributions, gifts, grants, and similar amounts not included above | $890,657 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $6,469,338 |
| Total Program Service Revenue | $577,571 |
| Investment income | $204 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $27,604 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $7,532,149 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $230,939 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $2,069,236 |
| Pension plan accruals and contributions | $62,062 |
| Other employee benefits | $224,739 |
| Payroll taxes | $166,215 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $148,337 |
| Fees for services: Accounting | $20,518 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $169,317 |
| Advertising and promotion | $0 |
| Office expenses | $26,562 |
| Information technology | $21,165 |
| Royalties | $0 |
| Occupancy | $351,707 |
| Travel | $37,778 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $16,145 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $54,711 |
| Insurance | $27,919 |
| All other expenses | $16,523 |
| Total functional expenses | $5,849,247 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $678,162 |
| Savings and temporary cash investments | $1,931,726 |
| Pledges and grants receivable | $1,693,916 |
| Accounts receivable, net | $203,006 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $120,161 |
| Net Land, buildings, and equipment | $93,001 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $1,261,977 |
| Total assets | $5,981,949 |
| Accounts payable and accrued expenses | $711,170 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $1,248,268 |
| Total liabilities | $1,959,438 |
| Net assets without donor restrictions | $3,024,854 |
| Net assets with donor restrictions | $997,657 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $5,981,949 |